Hubei Guangji Pharmaceutical Co Ltd
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. It also exports its products. The company was founded in 1969 and is based in Wuxue, China.
Hubei Guangji Pharmaceutical Co Ltd (000952) - Net Assets
Latest net assets as of September 2025: CN¥963.20 Million CNY
Based on the latest financial reports, Hubei Guangji Pharmaceutical Co Ltd (000952) has net assets worth CN¥963.20 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.58 Billion) and total liabilities (CN¥1.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥963.20 Million |
| % of Total Assets | 37.33% |
| Annual Growth Rate | 7.72% |
| 5-Year Change | -21.2% |
| 10-Year Change | 109.43% |
| Growth Volatility | 28.56 |
Hubei Guangji Pharmaceutical Co Ltd - Net Assets Trend (1996–2024)
This chart illustrates how Hubei Guangji Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hubei Guangji Pharmaceutical Co Ltd (1996–2024)
The table below shows the annual net assets of Hubei Guangji Pharmaceutical Co Ltd from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.08 Billion | -22.71% |
| 2023-12-31 | CN¥1.39 Billion | -6.66% |
| 2022-12-31 | CN¥1.49 Billion | +2.83% |
| 2021-12-31 | CN¥1.45 Billion | +6.23% |
| 2020-12-31 | CN¥1.37 Billion | +41.63% |
| 2019-12-31 | CN¥964.30 Million | +9.46% |
| 2018-12-31 | CN¥880.96 Million | +15.12% |
| 2017-12-31 | CN¥765.24 Million | +16.09% |
| 2016-12-31 | CN¥659.18 Million | +28.28% |
| 2015-12-31 | CN¥513.86 Million | +1.67% |
| 2014-12-31 | CN¥505.45 Million | -31.24% |
| 2013-12-31 | CN¥735.04 Million | -3.29% |
| 2012-12-31 | CN¥760.05 Million | -11.99% |
| 2011-12-31 | CN¥863.60 Million | +2.89% |
| 2010-12-31 | CN¥839.35 Million | +2.75% |
| 2009-12-31 | CN¥816.91 Million | +0.69% |
| 2008-12-31 | CN¥811.28 Million | +20.55% |
| 2007-12-31 | CN¥673.00 Million | +40.89% |
| 2006-12-31 | CN¥477.68 Million | -10.17% |
| 2005-12-31 | CN¥531.76 Million | +1.64% |
| 2004-12-31 | CN¥523.19 Million | +1.68% |
| 2003-12-31 | CN¥514.56 Million | +1.52% |
| 2002-12-31 | CN¥506.86 Million | +4.11% |
| 2001-12-31 | CN¥486.87 Million | +1.11% |
| 2000-12-31 | CN¥481.54 Million | +7.18% |
| 1999-12-31 | CN¥449.30 Million | +134.07% |
| 1998-12-31 | CN¥191.95 Million | +15.49% |
| 1997-12-31 | CN¥166.21 Million | +23.87% |
| 1996-12-31 | CN¥134.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hubei Guangji Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 586.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥207.39 Million | 19.47% |
| Common Stock | CN¥349.86 Million | 32.85% |
| Other Components | CN¥507.69 Million | 47.67% |
| Total Equity | CN¥1.06 Billion | 100.00% |
Hubei Guangji Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Hubei Guangji Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NICHOLS PLC LS-10
F:NRV
|
$234.98 Million |
|
Assystem SA
F:BZ1
|
$235.00 Million |
|
John Wood Group PLC
PINK:WDGJF
|
$235.02 Million |
|
Dong Nai Port JSC
VN:PDN
|
$235.10 Million |
|
DB Financial Investment Co Ltd
KO:016610
|
$234.84 Million |
|
Huatian Hotel Group Co Ltd
SHE:000428
|
$234.77 Million |
|
Msscorps Co Ltd
TW:6830
|
$234.76 Million |
|
Kaimei Electronic Corp
TW:2375
|
$234.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hubei Guangji Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,363,446,043 to 1,064,939,987, a change of -298,506,056 (-21.9%).
- Net loss of 295,291,149 reduced equity.
- Dividend payments of 50,461,528 reduced retained earnings.
- Share repurchases of 14,513,784 reduced equity.
- Other factors increased equity by 61,760,405.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-295.29 Million | -27.73% |
| Dividends Paid | CN¥50.46 Million | -4.74% |
| Share Repurchases | CN¥14.51 Million | -1.36% |
| Other Changes | CN¥61.76 Million | +5.8% |
| Total Change | CN¥- | -21.89% |
Book Value vs Market Value Analysis
This analysis compares Hubei Guangji Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 17.18x to 2.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | CN¥0.44 | CN¥7.63 | x |
| 1997-12-31 | CN¥0.55 | CN¥7.63 | x |
| 1998-12-31 | CN¥0.64 | CN¥7.63 | x |
| 1999-12-31 | CN¥1.49 | CN¥7.63 | x |
| 2000-12-31 | CN¥1.59 | CN¥7.63 | x |
| 2001-12-31 | CN¥1.61 | CN¥7.63 | x |
| 2002-12-31 | CN¥1.68 | CN¥7.63 | x |
| 2003-12-31 | CN¥1.70 | CN¥7.63 | x |
| 2004-12-31 | CN¥1.73 | CN¥7.63 | x |
| 2005-12-31 | CN¥1.76 | CN¥7.63 | x |
| 2006-12-31 | CN¥1.91 | CN¥7.63 | x |
| 2007-12-31 | CN¥2.21 | CN¥7.63 | x |
| 2008-12-31 | CN¥2.45 | CN¥7.63 | x |
| 2009-12-31 | CN¥2.61 | CN¥7.63 | x |
| 2010-12-31 | CN¥2.69 | CN¥7.63 | x |
| 2011-12-31 | CN¥2.67 | CN¥7.63 | x |
| 2012-12-31 | CN¥2.38 | CN¥7.63 | x |
| 2013-12-31 | CN¥2.47 | CN¥7.63 | x |
| 2014-12-31 | CN¥1.65 | CN¥7.63 | x |
| 2015-12-31 | CN¥1.69 | CN¥7.63 | x |
| 2016-12-31 | CN¥2.17 | CN¥7.63 | x |
| 2017-12-31 | CN¥2.51 | CN¥7.63 | x |
| 2018-12-31 | CN¥2.89 | CN¥7.63 | x |
| 2019-12-31 | CN¥3.22 | CN¥7.63 | x |
| 2020-12-31 | CN¥4.11 | CN¥7.63 | x |
| 2021-12-31 | CN¥4.25 | CN¥7.63 | x |
| 2022-12-31 | CN¥4.26 | CN¥7.63 | x |
| 2023-12-31 | CN¥3.85 | CN¥7.63 | x |
| 2024-12-31 | CN¥2.96 | CN¥7.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hubei Guangji Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -46.23%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 2.62x
- Recent ROE (-27.73%) is below the historical average (3.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 12.98% | 15.16% | 0.47x | 1.83x | CN¥4.00 Million |
| 1997 | 19.27% | 22.68% | 0.42x | 2.00x | CN¥15.41 Million |
| 1998 | 13.41% | 15.96% | 0.43x | 1.97x | CN¥6.55 Million |
| 1999 | 6.99% | 17.80% | 0.27x | 1.44x | CN¥-13.51 Million |
| 2000 | 6.36% | 22.82% | 0.20x | 1.40x | CN¥-17.54 Million |
| 2001 | 5.05% | 13.21% | 0.24x | 1.56x | CN¥-24.10 Million |
| 2002 | 3.92% | 9.83% | 0.25x | 1.62x | CN¥-30.82 Million |
| 2003 | 1.50% | 3.77% | 0.24x | 1.68x | CN¥-43.76 Million |
| 2004 | 1.57% | 2.97% | 0.30x | 1.74x | CN¥-44.06 Million |
| 2005 | 1.61% | 2.48% | 0.39x | 1.66x | CN¥-44.57 Million |
| 2006 | 3.28% | 4.03% | 0.50x | 1.64x | CN¥-32.06 Million |
| 2007 | 27.55% | 23.12% | 0.80x | 1.50x | CN¥117.08 Million |
| 2008 | 11.91% | 15.58% | 0.47x | 1.61x | CN¥14.27 Million |
| 2009 | 5.43% | 9.59% | 0.34x | 1.65x | CN¥-36.24 Million |
| 2010 | 1.73% | 2.89% | 0.35x | 1.72x | CN¥-66.67 Million |
| 2011 | 0.59% | 1.07% | 0.30x | 1.85x | CN¥-76.76 Million |
| 2012 | -13.29% | -24.25% | 0.25x | 2.16x | CN¥-167.46 Million |
| 2013 | 0.34% | 0.50% | 0.31x | 2.16x | CN¥-69.27 Million |
| 2014 | -43.91% | -45.02% | 0.31x | 3.18x | CN¥-268.55 Million |
| 2015 | 4.08% | 3.73% | 0.35x | 3.16x | CN¥-30.30 Million |
| 2016 | 21.69% | 19.85% | 0.44x | 2.50x | CN¥76.44 Million |
| 2017 | 13.86% | 13.13% | 0.49x | 2.16x | CN¥29.29 Million |
| 2018 | 19.66% | 20.35% | 0.50x | 1.94x | CN¥84.40 Million |
| 2019 | 9.05% | 11.89% | 0.41x | 1.84x | CN¥-9.09 Million |
| 2020 | 5.44% | 10.85% | 0.35x | 1.44x | CN¥-62.66 Million |
| 2021 | 7.53% | 13.15% | 0.41x | 1.40x | CN¥-36.14 Million |
| 2022 | 3.35% | 6.31% | 0.32x | 1.64x | CN¥-99.93 Million |
| 2023 | -10.29% | -19.01% | 0.24x | 2.22x | CN¥-276.59 Million |
| 2024 | -27.73% | -46.23% | 0.23x | 2.62x | CN¥-401.79 Million |
Industry Comparison
This section compares Hubei Guangji Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,550,361,810
- Average return on equity (ROE) among peers: -9.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hubei Guangji Pharmaceutical Co Ltd (000952) | CN¥963.20 Million | 12.98% | 1.68x | $234.89 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $177.19 Million | 13.55% | 0.63x | $201.14 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $280.61 Million | 7.70% | 0.99x | $310.45 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $638.18 Million | -181.03% | 3.22x | $202.85 Million |
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | $361.29 Million | 26.02% | 0.32x | $146.91 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.03 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $278.08 Million | 2.72% | 0.13x | $459.10 Million |
| Chongqing Lummy Pharmaceutical (300006) | $107.91 Million | 22.70% | 0.99x | $476.38 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.44 Billion | 5.91% | 0.29x | $1.19 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $1.53 Billion | 18.22% | 0.05x | $893.48 Million |